Patents by Inventor Yuji Ishichi
Yuji Ishichi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210269420Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.Type: ApplicationFiled: June 27, 2019Publication date: September 2, 2021Applicant: Takeda Pharmaceutical Company LimitedInventors: Tatsuhiko FUJIMOTO, Koichiro FUKUDA, Hiromichi SUGIMOTO, Kentaro RIKIMARU, Yoshihiro BANNO, Takahiro MATSUMOTO, Norihito TOKUNAGA, Yoshihide TOMATA, Yuji ISHICHI, Shogo MARUI, Tsuneo ODA, Tohru MIYAZAKI, Yasutaka HOASHI, Yasushi HATTORI, Yuichi KAJITA, Yuhei MIYANOHANA, Tatsuki KOIKE
-
Patent number: 9085578Abstract: The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.Type: GrantFiled: February 19, 2013Date of Patent: July 21, 2015Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Hiroyuki Nagamiya, Masato Yoshida, Masaki Seto, Shogo Marui, Tsuneo Oda, Yuji Ishichi, Hideo Suzuki, Tomokazu Kusumoto, Takatoshi Yogo, Chul Yun Rhim, Cheolhwan Yoon, Gil Nam Lee, Hyun Bin Kang, Kwang Ok Kim, Hye Sun Jeon
-
Publication number: 20150045349Abstract: The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.Type: ApplicationFiled: February 19, 2013Publication date: February 12, 2015Inventors: Hiroyuki Nagamiya, Masato Yoshida, Masaki Seto, Shogo Marui, Tsuneo Oda, Yuji Ishichi, Hideo Suzuki, Tomokazu Kusumoto, Takatoshi Yogo, Chul Yun Rhim, Cheolhwan Yoon, Gil Nam Lee, Hyun Bin Kang, Kwang Ok Kim, Hye Sun Jeon
-
Patent number: 8722662Abstract: Provided is a compound having a monoamine reuptake inhibitory activity, which is represented by the formula (I) wherein ring A is an optionally substituted 6-membered aromatic ring, ring B is the substituents on ring A are optionally bonded to form, together with ring A, an optionally substituted 9- or 10-membered aromatic fused ring, and other symbols are as defined in the specification, or a salt thereof.Type: GrantFiled: October 5, 2011Date of Patent: May 13, 2014Assignee: Takeda Pharmaceutical Company LimitedInventors: Yuji Ishichi, Masami Yamada, Taku Kamei, Ikuo Fujimori, Yoshihisa Nakada, Tomoya Yukawa, Nobuki Sakauchi, Yusuke Ohba, Tetsuya Tsukamoto
-
Publication number: 20130267494Abstract: Provided is a compound having a monoamine reuptake inhibitory activity, which is represented by the formula (I) wherein ring A is an optionally substituted 6-membered aromatic ring, ring B is the substituents on ring A are optionally bonded to form, together with ring A, an optionally substituted 9- or 10-membered aromatic fused ring, and other symbols are as defined in the specification, or a salt thereof.Type: ApplicationFiled: October 5, 2011Publication date: October 10, 2013Inventors: Yuji Ishichi, Masami Yamada, Taku Kamei, Ikuo Fujimori, Yoshihisa Nakada, Tomoya Yukawa, Nobuki Sakauchi, Yusuke Ohba, Tetsuya Tsukamoto
-
Patent number: 8252814Abstract: Agents for improving potency of the urinary bladder which comprise an amine compound of non-carbamate-type having an acetylcholinesterase-inhibiting action. Particularly, crystals of a tricyclic, condensed, heterocyclic derivative are provided, which possess an excellent action to inhibit acetylcholinesterase and an action to improve the excretory potency of the urinary bladder. As an example, crystals of 8-[3-[1-[(3-fluorophenyl)-methyl]-4-piperidinyl]-1-oxopropyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one or a salt thereof and pharmaceutical compositions containing them are disclosed.Type: GrantFiled: July 17, 2008Date of Patent: August 28, 2012Assignee: Takeda Pharmaceutical Company LimitedInventors: Yuji Ishihara, Takayuki Doi, Hiroshi Nagabukuro, Yuji Ishichi
-
Publication number: 20120088748Abstract: Provided is a compound having a monoamine reuptake inhibitory activity, which is represented by the formula (I) wherein ring A is an optionally substituted 6-membered aromatic ring, ring B is the substituents on ring A are optionally bonded to form, together with ring A, an optionally substituted 9- or 10-membered aromatic fused ring, and other symbols are as defined in the specification, or a salt thereof.Type: ApplicationFiled: October 5, 2011Publication date: April 12, 2012Inventors: Yuji Ishichi, Masami Yamada, Taku Kamei, Ikuo Fujimori, Yoshihisa Nakada, Tomoya Yukawa, Nobuki Sakauchi, Yusuke Ohba, Tetsuya Tsukamoto
-
Patent number: 7625887Abstract: It is intended to provide a TGR5 receptor agonist containing a fused ring compound represented by the following general formula, its salt or a prodrug thereof: (1) wherein ring A represents an optionally substituted aromatic ring; and the ring B? represents a 5- to 8-membered ring having one or more substituents; which is useful in treating various diseases.Type: GrantFiled: January 27, 2004Date of Patent: December 1, 2009Assignee: Takeda Pharmaceutical Company LimitedInventors: Fumio Itoh, Shuji Hinuma, Naoyuki Kanzaki, Yuji Kawamata, Taisuke Tawaraishi, Yuji Ishichi, Mariko Hirohashi
-
Publication number: 20090264467Abstract: Agents for improving potency of the urinary bladder which comprise an amine compound of non-carbamate-type having an acetylcholinesterase-inhibiting action. Particularly, crystals of a tricyclic, condensed, heterocyclic derivative are provided, which possess an excellent action to inhibit acetylcholinesterase and an action to improve the excretory potency of the urinary bladder. As an example, crystals of 8-[3-[1-[(3-fluorophenyl)-methyl]-4-piperidinyl]-1-oxopropyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one or a salt thereof and pharmaceutical compositions containing them are disclosed.Type: ApplicationFiled: July 17, 2008Publication date: October 22, 2009Inventors: Yuji Ishihara, Takayuki Doi, Hiroshi Nagabukuro, Yuji Ishichi
-
Patent number: 7462628Abstract: Preventives/remedies for voiding disturbance containing a compound having both of an acetylcholinesterase inhibitory action and an ?1 antagonistic action which exhibits an excellent effect of improving the urinary function of the bladder (i.e., effects of improving urine flow rate and voiding efficiency) without affecting the urinary pressure or the blood pressure.Type: GrantFiled: January 18, 2006Date of Patent: December 9, 2008Assignee: Takeda Pharmaceutical Company LimitedInventors: Yuji Ishihara, Yuji Ishichi, Takayuki Doi, Hiroshi Nagabukuro, Naoyuki Kanzaki, Motoki Ikeuchi
-
Publication number: 20070099986Abstract: A compound represented by the formula: wherein Ar represents a group represented by the formula: (wherein Y represents methylene or an oxygen atom, R1 represents aminosulfonyl, C1-6 alkylaminosulfonyl, C1-6 alkylcarbonylamino or C1-6 alkylsulfonylamino, R2 represents a hydrogen atom or C1-6 alkyl, R3 represents C1-6 alkyl, and R4 represents a hydrogen atom or C1-6 alkyl); X represents a carbonyl group, or a methylene group which may be substituted with a hydroxy group; and L represents an optionally substituted C4-5 alkylene group, or a salt thereof is provided.Type: ApplicationFiled: October 31, 2006Publication date: May 3, 2007Inventors: Yuji Ishichi, Koichi Iwanaga, Tomomi Ikemoto, Hiroaki Yamamoto, Shokyo Miki
-
Publication number: 20060281725Abstract: Agents for improving potentcy of the urinary bladder which comprise an amine compound of non-carbamate-type having an acetylcholinesterase-inhibiting action. Particularly, crystals of a tricyclic, condensed, heterocyclic derivative are provided, which possess an excellent action to inhibit acetylcholinesterase and an action to improve the excretory potency of the urinary bladder. As an example, crystals of of 8-[3-[1-[(3-fluorophenyl)-methyl]-4-piperidinyl]-1-oxopropyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one or a salt thereof and pharmaceutical compositions containing them are disclosed.Type: ApplicationFiled: June 28, 2006Publication date: December 14, 2006Inventors: Yuji Isihara, Takayuki Doi, Hiroshi Nagabukuro, Yuji Ishichi
-
Patent number: 7138533Abstract: Preventives/remedies for voiding disturbance containing a compound having both of an acetylcholinesterase inhibitory action and an ?1 antagonistic action which exhibits an excellent effect of improving the urinary function of the bladder (i.e., effects of improving urine flow rate and voiding efficiency) without affecting the urinary pressure or the blood pressure.Type: GrantFiled: September 8, 2004Date of Patent: November 21, 2006Assignee: Takeda Pharmaceutical Company LimitedInventors: Yuji Ishihara, Yuji Ishichi, Takayuki Doi, Hiroshi Nagabukuro, Naoyuki Kanzaki, Motoki Ikeuchi
-
Patent number: 7132547Abstract: Preventives/remedies for voiding disturbance containing a compound having both of an acetylcholinesterase inhibitory action and an ?1 antagonistic action which exhibits an excellent effect of improving the urinary function of the bladder (i.e., effects of improving urine flow rate and voiding efficiency) without affecting the urinary pressure or the blood pressure.Type: GrantFiled: December 26, 2002Date of Patent: November 7, 2006Assignee: Takeda Pharmaceutical Company LimitedInventors: Yuji Ishihara, Yuji Ishichi, Takayuki Doi, Hiroshi Nagabukuro, Naoyuki Kanzaki, Motoki Ikeuchi
-
Publication number: 20060211675Abstract: Preventives/remedies for voiding disturbance containing a compound having both of an acetylcholinesterase inhibitory action and an al antagonistic action which exhibits an excellent effect of improving the urinary function of the bladder (i.e., effects of improving urine flow rate and voiding efficiency) without affecting the urinary pressure or the blood pressure.Type: ApplicationFiled: January 18, 2006Publication date: September 21, 2006Inventors: Yuji Ishihara, Yuji Ishichi, Takayuki Doi, Hiroshi Nagabukuro, Naoyuki Kanzaki, Motoki Ikeuchi
-
Publication number: 20060199795Abstract: The present invention provides a TGR5 receptor agonist comprising a fused ring compound represented by the formula wherein ring A is an optionally substituted aromatic ring; and ring B? is a 5- to 8-membered ring having one or more substituents or a salt thereof or a prodrug thereof, which is useful for the treatment of various diseases.Type: ApplicationFiled: January 27, 2004Publication date: September 7, 2006Inventors: Fumio Itoh, Shuji Hinuma, Naoyuki Kanzaki, Takashi Miki, Yuji Kawamata, Satoru Oi, Taisuke Tawaraishi, Yuji Ishichi, Mariko Hirohashi
-
Publication number: 20060063769Abstract: Preventives/remedies for voiding disturbance containing a compound having both of an acetylcholinesterase inhibitory action and an ?1 antagonistic action which exhibits an excellent effect of improving the urinary function of the bladder (i.e., effects of improving urine flow rate and voiding efficiency) without affecting the urinary pressure or the blood pressure.Type: ApplicationFiled: December 26, 2002Publication date: March 23, 2006Inventors: Yuji Ishihara, Yuji Ishichi, Takayuki Doi, Hiroshi Nagabukuro, Naoyuki Kanzaki, Motoki Ikeuchi
-
Publication number: 20050197362Abstract: Preventives/remedies for voiding disturbance containing a compound having both of an acetylcholinesterase inhibitory action and an ?1 antagonistic action which exhibits an excellent effect of improving the urinary function of the bladder (i.e., effects of improving urine flow rate and voiding efficiency) without affecting the urinary pressure or the blood pressure.Type: ApplicationFiled: September 8, 2004Publication date: September 8, 2005Inventors: Yuji Ishihara, Yuji Ishichi, Takayuki Doi, Hiroshi Nagabukuro, Naoyuki Kanzaki, Motoki Ikeuchi
-
Publication number: 20040116457Abstract: Agents for improving excretory potency of the urinary bladder which comprises an amine compound of non-carbamate-type having an acetylcholinesterase-inhibiting action.Type: ApplicationFiled: December 4, 2003Publication date: June 17, 2004Inventors: Yuji Ishihara, Takayuki Doi, Hiroshi Nagabukuro, Yuji Ishichi
-
Publication number: 20020177593Abstract: Agents for improving potentcy of the urinary bladder which comprises an amine compound of non-carbamate-type having an acetylcholinesterase-inhibiting action. Particularly, crystals of a tricyclic, condensed, heterocyclic derivative are provided, which possess an excellent action to inhibit acetylcholine esterase and an action to improve the excretory potency of urinary bladder. As an example, crystals of of 8-[3-[1-[(3-fluorophenyl)-methyl]-4-piperidinyl]-1-oxopropyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one or a salt thereof and pharmaceutical compositions containing them are disclosed.Type: ApplicationFiled: September 24, 2001Publication date: November 28, 2002Inventors: Yuji Ishihara, Takayuki Doi, Hiroshi Nagabukuro, Yuji Ishichi